Ieq Capital LLC Takes $2.27 Million Position in Teladoc Health, Inc. $TDOC

Ieq Capital LLC purchased a new position in shares of Teladoc Health, Inc. (NYSE:TDOC) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 268,062 shares of the health services provider’s stock, valued at approximately $2,273,000.

A number of other institutional investors have also added to or reduced their stakes in the company. Monaco Asset Management SAM purchased a new stake in shares of Teladoc Health during the second quarter valued at approximately $26,864,000. Tejara Capital Ltd bought a new position in Teladoc Health in the 4th quarter valued at $1,114,000. Jupiter Asset Management Ltd. increased its position in shares of Teladoc Health by 293.9% during the 4th quarter. Jupiter Asset Management Ltd. now owns 3,860,076 shares of the health services provider’s stock valued at $27,021,000 after purchasing an additional 2,880,008 shares during the last quarter. Nano Cap New Millennium Growth Fund L P purchased a new position in shares of Teladoc Health in the 4th quarter worth about $1,225,000. Finally, Pale Fire Capital SE grew its position in Teladoc Health by 74.8% during the first quarter. Pale Fire Capital SE now owns 3,398,491 shares of the health services provider’s stock valued at $18,522,000 after buying an additional 1,454,288 shares during the period. 76.82% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Teladoc Health news, insider Adam C. Vandervoort sold 7,906 shares of the firm’s stock in a transaction dated Tuesday, June 2nd. The stock was sold at an average price of $7.63, for a total value of $60,322.78. Following the completion of the transaction, the insider owned 110,261 shares in the company, valued at $841,291.43. This trade represents a 6.69% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Charles Divita III sold 19,132 shares of Teladoc Health stock in a transaction dated Tuesday, June 2nd. The shares were sold at an average price of $7.63, for a total value of $145,977.16. Following the transaction, the chief executive officer directly owned 389,894 shares of the company’s stock, valued at $2,974,891.22. The trade was a 4.68% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 39,195 shares of company stock valued at $299,058 in the last ninety days. 0.70% of the stock is owned by company insiders.

Teladoc Health Trading Up 0.1%

Shares of TDOC stock opened at $6.21 on Wednesday. The firm’s 50 day moving average is $8.03 and its 200 day moving average is $6.62. The stock has a market capitalization of $1.13 billion, a P/E ratio of -6.27 and a beta of 2.12. Teladoc Health, Inc. has a 12 month low of $4.40 and a 12 month high of $9.89.

Teladoc Health (NYSE:TDOC) last released its quarterly earnings data on Wednesday, July 29th. The health services provider reported ($0.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.04. Teladoc Health had a negative net margin of 7.13% and a negative return on equity of 12.15%. The business had revenue of $606.93 million during the quarter, compared to analyst estimates of $615.44 million. During the same period in the previous year, the business earned ($0.19) EPS. Teladoc Health’s revenue was down 4.0% compared to the same quarter last year. Teladoc Health has set its Q3 2026 guidance at -0.300–0.200 EPS and its FY 2026 guidance at -1.000–0.750 EPS. On average, equities analysts predict that Teladoc Health, Inc. will post -0.89 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on TDOC. Weiss Ratings restated a “sell (d-)” rating on shares of Teladoc Health in a report on Wednesday, August 19th. Citigroup dropped their price objective on Teladoc Health from $11.00 to $7.50 and set a “neutral” rating on the stock in a research note on Monday, August 3rd. Canaccord Genuity Group decreased their target price on Teladoc Health from $11.00 to $10.00 and set a “buy” rating for the company in a research report on Thursday, July 30th. Finally, Bank of America boosted their target price on Teladoc Health from $9.00 to $10.50 and gave the company a “buy” rating in a research note on Tuesday, July 7th. Five equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $7.54.

Teladoc Health Company Profile

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.